Results 31 to 40 of about 53,817 (192)

Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways

Scientific Reports, 2020
Renal fibrosis is a failed regenerative process that facilitates chronic kidney disease progression. The current study was designed to study the effect of erlotinib, a receptor tyrosine kinase inhibitor, on the progression of renal fibrosis.
Ahmed M. Awad, Mohamed A. Saleh, Nashwa M. Abu-Elsaad, Tarek M. Ibrahim   +3 more
doaj   +1 more source

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer

Case Reports in Oncology, 2021
Acute generalized exanthematous pustulosis (AGEP) is a rare drug-related adverse skin reaction caused mainly by antibiotics. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat lung cancer.
Natsuko Komiya, Koichiro Takahashi, Go Kato, Mio Kubota, Hiroki Tashiro, Chiho Nakashima, Tomomi Nakamura, Kentaro Iwanaga, Shinya Kimura, Naoko Sueoka-Aragane   +9 more
doaj   +1 more source

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

Frontiers in Pharmacology, 2018
The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The
Cong Wang, Cong Wang, Fang Chen, Fang Chen, Yichen Liu, Qingqing Xu, Liang Guo, Xiaoqing Zhang, Yunfeng Ruan, Ye Shi, Lu Shen, Mo Li, Huihui Du, Xiaofang Sun, Jingsong Ma, Lin He, Shengying Qin, Shengying Qin, Shengying Qin   +18 more
doaj   +1 more source

Results from the phase iii randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage iiib or iv non–small-cell lung cancer: METLung [PDF]

, 2017
Purpose\ud \ud The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non–small-cell lung cancer selected by MET immunohistochemistry whose disease had ...
David R. Spigel, Martin J. Edelman, David S. Shames, Spigel, David R., See Phan, Tony Mok, O'Byrne, Kenneth, Paz Ares, Luis Gonzaga, Spigel, David R, Mocci, Simonetta, Phan, See, Virginia E. Paton, Shames, David S., Shames, David S, Luis Paz-Ares, Paton, Viginia E., Kenneth O’Byrne, Simonetta Mocci, Dustin Smith, Paz-Ares, Luis, Smith, Dustin, Yu, Wei, O'Byrne, Kenneth J., Edelman, Martin J, Edelman, Martin J., Paton, Virginia E, Mok, Tony, Wei Yu   +27 more
core   +2 more sources

Erlotinib: Um caso clínico de sucesso e algumas notas sobre a toxicidade hepática

Revista Portuguesa de Pneumologia, 2008
Resumo: Apresenta-se o caso clínico de uma mulher com adenocarcinoma do pulmão em que se conseguiu o controlo da doença, durante quinze meses, com erlotinib em segunda linha.
Agostinho Costa
doaj   +1 more source

Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma

Animal Models and Experimental Medicine, EarlyView.
A zebrafish xenograft model accurately distinguishes metastatic from non‐metastatic HNSCC and recapitulates cisplatin sensitivity/resistance patterns. Using patient‐derived tumors, it predicts individual therapeutic responses, offering a rapid, clinically applicable platform for guiding personalized treatment. Abstract Background Head and neck squamous
Lu Chen, Shu Sun, Yujia Liu, Liehao Jiang, Cuiyun Wu, Ting Liu, Yujiao Zhao, Yuwei Liu, Lu Liu, Qi Wang, Xiaowei Zheng, Ping Huang   +11 more
wiley   +1 more source

From Real World Data to Real Impact: A Co-Medication Framework for Lung Cancer to Advance DDI Assessment and Patient-Centric Drug Development. [PDF]

Clin Transl Sci
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Biju M, Choi H, Madari S, Carlisle A, Sharma A, Kunz C, Huang F.   +6 more
europepmc   +2 more sources

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source